| Year |
Citation |
Score |
| 2023 |
Baker SD, Bates SE, Brooks GA, Dahut WL, Diasio RB, El-Deiry WS, Evans WE, Figg WD, Hertz DL, Hicks JK, Kamath S, Kasi PM, Knepper TC, McLeod HL, O'Donnell PH, ... ... Rudek MA, et al. Testing: Time to Put Patient Safety First. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2202364. PMID 36821823 DOI: 10.1200/JCO.22.02364 |
0.324 |
|
| 2020 |
Connolly RM, Laille E, Vaishampayan U, Chung V, Kelly K, Dowlati A, Alese OB, Harvey RD, Haluska P, Siu LL, Kummar S, Piekarz RL, Ivy SP, Anders NM, Downs M, ... ... Rudek MA, et al. Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32816943 DOI: 10.1158/1078-0432.Ccr-20-1412 |
0.38 |
|
| 2020 |
Murphy AG, Zahurak M, Shah M, Weekes CD, Hansen A, Siu LL, Spreafico A, LoConte N, Anders NM, Miles T, Rudek MA, Doyle LA, Nelkin B, Maitra A, Azad NS, et al. A Phase I Study of Dinaciclib in Combination With MK-2206 in Patients With Advanced Pancreatic Cancer. Clinical and Translational Science. PMID 32738099 DOI: 10.1111/Cts.12802 |
0.45 |
|
| 2020 |
Grossman SA, Romo CG, Rudek MA, Supko J, Fisher J, Nabors LB, Wen PY, Peereboom DM, Ellingson BM, Elmquist W, Barker FG, Kamson D, Sarkaria JN, Timmer W, Bindra RS, et al. Baseline Requirements for Novel Agents Being Considered for Phase II/III Brain Cancer Efficacy Trials:Conclusions from the Adult Brain Tumor Consortium's First Workshop on CNS Drug Delivery. Neuro-Oncology. PMID 32506123 DOI: 10.1093/Neuonc/Noaa142 |
0.305 |
|
| 2019 |
Pratz KW, Rudek MA, Smith BD, Karp J, Gojo I, Dezern A, Jones RJ, Greer J, Gocke C, Baer MR, Duong VH, Rosner G, Zahurak M, Wright JJ, Emadi A, et al. A prospective study of peri-transplant sorafenib for FLT3-ITD AML patients undergoing allogeneic transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 31550496 DOI: 10.1016/J.Bbmt.2019.09.023 |
0.305 |
|
| 2019 |
Kurzrock R, Ball DW, Zahurak ML, Nelkin BD, Subbiah V, Ahmed S, O'Connor A, Karunsena E, Parkinson RM, Bishop JA, Ha Y, Sharma R, Gocke CD, Zinner R, Rudek MA, et al. The VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31186313 DOI: 10.1158/1078-0432.Ccr-18-1881 |
0.323 |
|
| 2019 |
Gaillard SL, Zahurak M, Sharma A, Reiss KA, Sartorius-Mergenthaler S, Downs M, Anders NM, Ahuja N, Rudek MA, Azad N. A phase 1 trial of the oral DNA methyltransferase inhibitor CC-486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors. Cancer. PMID 31012962 DOI: 10.1002/Cncr.32138 |
0.354 |
|
| 2019 |
Saif MW, Rosen L, Rudek MA, Sun W, Shepard DR, Becerra C, Yamashita F, Bebeau P, Winkler R. Open-label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment (PI: Dr Saif). British Journal of Clinical Pharmacology. PMID 30628113 DOI: 10.1111/Bcp.13856 |
0.364 |
|
| 2019 |
Rubinstein PG, Moore PC, Bimali M, Chadburn A, Cesarman E, Rudek M, Ratner L, Ambinder RF, Henry DH, Barta SK, Ghesquieres H, Coppo P, Delobel P, Boue F, Galicier L, et al. Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085 Blood. 134: 130-130. DOI: 10.1182/Blood-2019-126787 |
0.31 |
|
| 2018 |
Bharathy N, Berlow NE, Wang E, Abraham J, Settelmeyer TP, Hooper JE, Svalina MN, Ishikawa Y, Zientek K, Bajwa Z, Goros MW, Hernandez BS, Wolff JE, Rudek MA, Xu L, et al. The HDAC3-SMARCA4-miR-27a axis promotes expression of the fusion oncogene in rhabdomyosarcoma. Science Signaling. 11. PMID 30459282 DOI: 10.1126/Scisignal.Aau7632 |
0.308 |
|
| 2018 |
Singh R, Mehrotra S, Gopalakrishnan M, Gojo I, Karp JE, Greer JM, Chen A, Piekarz R, Kiesel BF, Gobburu J, Rudek MA, Beumer JH. Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias. Cancer Chemotherapy and Pharmacology. PMID 30456480 DOI: 10.1007/S00280-018-3731-4 |
0.358 |
|
| 2018 |
Reid E, Suneja G, Ambinder RF, Ard K, Baiocchi R, Barta SK, Carchman E, Cohen A, Gupta N, Johung KL, Klopp A, LaCasce AS, Lin C, Makarova-Rusher OV, Mehta A, ... ... Rudek MA, et al. Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 16: 986-1017. PMID 30099375 DOI: 10.6004/Jnccn.2018.0066 |
0.321 |
|
| 2018 |
Liu T, Ivaturi V, Sabato P, Gobburu JVS, Greer JM, Wright JJ, Smith BD, Pratz KW, Rudek MA. Sorafenib Dose Recommendation in Acute Myeloid Leukemia Based on Exposure-FLT3 Relationship. Clinical and Translational Science. PMID 29702736 DOI: 10.1111/Cts.12555 |
0.364 |
|
| 2018 |
Ramos JC, Sparano JA, Rudek MA, Moore PC, Cesarman E, Reid EG, Henry D, Ratner L, Aboulafia D, Lee JY, Ambinder RF, Mitsuyasu R, Noy A. Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075). Clinical Lymphoma, Myeloma & Leukemia. PMID 29426719 DOI: 10.1016/J.Clml.2018.01.004 |
0.305 |
|
| 2018 |
Jackson S, Weingart J, Nduom EK, Harfi TT, George RT, McAreavey D, Ye X, Anders NM, Peer C, Figg WD, Gilbert M, Rudek MA, Grossman SA. The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. Fluids and Barriers of the Cns. 15: 2. PMID 29332604 DOI: 10.1186/S12987-017-0088-8 |
0.448 |
|
| 2018 |
Kalin JH, Wu M, Gomez AV, Song Y, Das J, Hayward D, Adejola N, Wu M, Panova I, Chung HJ, Kim E, Roberts HJ, Roberts JM, Prusevich P, Jeliazkov JR, ... ... Rudek MA, et al. Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors. Nature Communications. 9: 53. PMID 29302039 DOI: 10.1038/S41467-017-02242-4 |
0.317 |
|
| 2018 |
Ansari A, Miyashita T, Lay F, Ahmed AK, Matsangos AE, Born L, Ng C, Cohen RM, Stricker-Krongrad A, Salimian K, Marti GP, Mukaisho K, Pezhouh MK, Marrone K, Meltzer SJ, ... Rudek MA, et al. Targeting the hedgehog pathway in esophageal adenocarcinoma (EAC) using Itraconazole. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.E13552 |
0.324 |
|
| 2017 |
Tan CRC, Barta SK, Lee J, Rudek MA, Sparano JA, Noy A. Combination antiretroviral therapy accelerates immune recovery in patients with HIV-related lymphoma treated with EPOCH: a comparison within one prospective trial AMC034. Leukemia & Lymphoma. 1-10. PMID 29160731 DOI: 10.1080/10428194.2017.1403597 |
0.319 |
|
| 2017 |
Uldrick TS, Ison G, Rudek MA, Noy A, Schwartz K, Bruinooge S, Schenkel C, Miller B, Dunleavy K, Wang J, Zeldis J, Little RF. Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research HIV Working Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017737338. PMID 28968173 DOI: 10.1200/Jco.2017.73.7338 |
0.323 |
|
| 2017 |
Bruner JK, Ma HS, Li L, Qin ACR, Rudek MA, Jones RJ, Levis MJ, Pratz KW, Pratilas CA, Small D. Adaptation to TKI treatment reactivates ERK signaling in tyrosine kinase-driven leukemias and other malignancies. Cancer Research. PMID 28923853 DOI: 10.1158/0008-5472.Can-16-2593 |
0.338 |
|
| 2017 |
Mehrotra S, Gopalakrishnan M, Gobburu J, Ji JJ, Greer JM, Piekarz RL, Karp J, Pratz KW, Rudek MA. Exposure-Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28751440 DOI: 10.1158/1078-0432.Ccr-17-0143 |
0.384 |
|
| 2017 |
Uldrick TS, Gonçalves PH, Wyvill KM, Peer CJ, Bernstein W, Aleman K, Polizzotto MN, Venzon D, Steinberg SM, Marshall V, Whitby D, Little RF, Wright JJ, Rudek MA, Figg WD, et al. A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma. The Oncologist. PMID 28341759 DOI: 10.1634/Theoncologist.2016-0486 |
0.517 |
|
| 2017 |
Connolly RM, Rudek MA, Piekarz R. Entinostat: a promising treatment option for patients with advanced breast cancer. Future Oncology (London, England). PMID 28326839 DOI: 10.2217/Fon-2016-0526 |
0.375 |
|
| 2017 |
Mehrotra S, Gopalakrishnan M, Gobburu J, Greer JM, Piekarz R, Karp JE, Pratz K, Rudek MA. Population pharmacokinetics and site of action exposures of veliparib with topotecan plus carboplatin in patients with hematological malignancies. British Journal of Clinical Pharmacology. PMID 28156017 DOI: 10.1111/Bcp.13253 |
0.349 |
|
| 2017 |
Paller CJ, Heath EI, Taplin M, Stein MN, Bubley GJ, Pili R, Mayer TM, Zhou XC, Hudson T, Abbas M, Anders N, Dowling D, KIng S, Drake CG, Antonarakis ES, ... ... Rudek MA, et al. A phase II study of muscadine grape skin extract in men with biochemically recurrent prostate cancer. Journal of Clinical Oncology. 35: 248-248. DOI: 10.1200/Jco.2017.35.6_Suppl.248 |
0.37 |
|
| 2017 |
Saif WM, Rosen LS, Rudek MA, Sun W, Shepard DR, Becerra C, Yamashita F, Bebeau P, Winkler R. An open-label expanded-access study to evaluate the safety, tolerability, and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and hepatic impairment. Journal of Clinical Oncology. 35: 2559-2559. DOI: 10.1200/Jco.2017.35.15_Suppl.2559 |
0.38 |
|
| 2017 |
Jackson S, Weingart J, Nduom E, Holdhoff M, Blakeley J, Piotrowski AF, Abd T, George R, McAreavey D, Ye X, Anders N, Peer C, Barnes J, Figg W, Rudek M, et al. ACTR-85. THE EFFECT OF REGADENOSON ON TEMOZOLOMIDE NEUROPHARMACOKINETICS IN GLIOBLASTOMA PATIENTS MEASURED BY INTRACEREBRAL MICRODIALYSIS Neuro-Oncology. 19: vi19-vi19. DOI: 10.1093/Neuonc/Nox168.071 |
0.422 |
|
| 2016 |
Connolly R, Li H, Jankowitz RC, Zhang Z, Rudek MA, Jeter SC, Slater S, Powers P, Wolff AC, Fetting JH, Brufsky AM, Piekarz R, Ahuja N, Laird PW, Shen H, et al. Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27979916 DOI: 10.1158/1078-0432.Ccr-16-1729 |
0.332 |
|
| 2016 |
Pratz KW, Rudek MA, Gojo I, Litzow MR, McDevitt MA, Ji JJ, Karnitz L, Herman JG, Kinders R, Smith BD, Gore SD, Carraway H, Showel MM, Gladstone DE, Levis MJ, et al. A Phase I study of topotecan, carboplatin and the PARP inhibitor veliparib in acute leukemias, aggressive myeloproliferative neoplasms and chronic myelomonocytic leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27551000 DOI: 10.1158/1078-0432.Ccr-16-1274 |
0.347 |
|
| 2016 |
Gojo I, Beumer JH, Pratz KW, McDevitt MA, Baer MR, Blackford AL, Smith BD, Gore SD, Carraway H, Showel MM, Levis MJ, Dezern A, Gladstone DE, Ji JJ, Wang L, ... ... Rudek MA, et al. A phase 1 study of the PARP inhibitor veliparib in combination with temozolomide in acute myeloid leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27503200 DOI: 10.1158/1078-0432.Ccr-16-0984 |
0.35 |
|
| 2016 |
Mansfield AS, Rudek MA, Vulih D, Smith GL, Harris PJ, Ivy SP. The effect of hepatic impairment on outcomes in phase 1 clinical trials in cancer subjects. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27189163 DOI: 10.1158/1078-0432.Ccr-16-0449 |
0.303 |
|
| 2016 |
Fox JM, Moynihan JR, Mott BT, Mazzone JR, Anders NM, Brown PA, Rudek MA, Liu JO, Arav-Boger R, Posner GH, Civin CI, Chen X. Artemisinin-derived dimer ART-838 potently inhibited human acute leukemias, persisted in vivo, and synergized with antileukemic drugs. Oncotarget. PMID 26771236 DOI: 10.18632/Oncotarget.6896 |
0.325 |
|
| 2016 |
Çelik H, Bulut G, Han J, Graham GT, Minas TZ, Conn EJ, Hong S, Pauly GT, Hayran M, Li X, Özdemirli M, Ayhan A, Rudek MA, Toretsky JA, Üren A. Abstract 2446: Ezrin inhibition up-regulates stress response gene expression and blocks osteosarcoma metastasis Cancer Research. 76: 2446-2446. DOI: 10.1158/1538-7445.Am2016-2446 |
0.339 |
|
| 2015 |
Rudek MA, Dasari A, Laheru D, He P, Jin R, Walker R, Taylor GE, Jimeno A, Donehower RC, Hidalgo M, Messersmith WA, Purcell WT. Phase I Study of ABT-751 in Combination with CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients with Advanced Colorectal Cancer. Journal of Clinical Pharmacology. PMID 26632033 DOI: 10.1200/Jco.2006.24.18_Suppl.13553 |
0.361 |
|
| 2015 |
Rudek MA, Graham RA, Ratain MJ. Harmonization of Renal Function Assessment Is Needed During Early Clinical Development of Oncology Drugs. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26628472 DOI: 10.1200/Jco.2015.64.2553 |
0.315 |
|
| 2015 |
Deeken JF, Beumer JH, Anders NM, Wanjiku T, Rusnak M, Rudek MA. Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib. Cancer Chemotherapy and Pharmacology. 76: 813-9. PMID 26330331 DOI: 10.1007/S00280-015-2856-Y |
0.366 |
|
| 2015 |
Beumer JH, Pillai VC, Parise RA, Christner SM, Kiesel BF, Rudek MA, Venkataramanan R. Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation. British Journal of Clinical Pharmacology. 80: 1097-108. PMID 26178713 DOI: 10.1111/Bcp.12723 |
0.345 |
|
| 2015 |
Anders NM, Wanjiku TM, He P, Azad NS, Rudek MA. A robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of 5-azacytidine. Biomedical Chromatography : Bmc. PMID 26174363 DOI: 10.1002/Bmc.3562 |
0.355 |
|
| 2015 |
Paller CJ, Rudek MA, Zhou XC, Wagner WD, Hudson TS, Anders N, Hammers HJ, Dowling D, King S, Antonarakis ES, Drake CG, Eisenberger MA, Denmeade SR, Rosner GL, Carducci MA. A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination. The Prostate. PMID 26012728 DOI: 10.1002/Pros.23024 |
0.312 |
|
| 2015 |
Bol GM, Vesuna F, Xie M, Zeng J, Aziz K, Gandhi N, Levine A, Irving A, Korz D, Tantravedi S, Heerma van Voss MR, Gabrielson K, Bordt EA, Polster BM, Cope L, ... ... Rudek MA, et al. Targeting DDX3 with a small molecule inhibitor for lung cancer therapy. Embo Molecular Medicine. 7: 648-69. PMID 25820276 DOI: 10.15252/Emmm.201404368 |
0.342 |
|
| 2015 |
Wilky BA, Rudek MA, Ahmed S, Laheru DA, Cosgrove D, Donehower RC, Nelkin B, Ball D, Doyle LA, Chen H, Ye X, Bigley G, Womack C, Azad NS. A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours. British Journal of Cancer. 112: 24-31. PMID 25268371 DOI: 10.1038/Bjc.2014.515 |
0.395 |
|
| 2015 |
Wicks RT, Azadi J, Mangraviti A, Zhang I, Hwang L, Joshi A, Bow H, Hutt-Cabezas M, Martin KL, Rudek MA, Zhao M, Brem H, Tyler BM. Local delivery of cancer-cell glycolytic inhibitors in high-grade glioma. Neuro-Oncology. 17: 70-80. PMID 25053853 DOI: 10.1093/Neuonc/Nou143 |
0.366 |
|
| 2015 |
Reiss KA, Rudek MA, Sartorius-Mergenthaler S, Downs M, Cosgrove D, Gaillard S, Baylin S, Ahuja N, Azad NS. A phase I trial of oral 5-azacitidine in combination with romidepsin in advanced solid tumors with an expansion cohort in virally mediated cancers and liposarcoma. Journal of Clinical Oncology. 33: TPS2619-TPS2619. DOI: 10.1200/Jco.2015.33.15_Suppl.Tps2619 |
0.373 |
|
| 2015 |
Pratz KW, Gojo I, Karp JE, Luznik L, Smith BD, Jones RJ, Greer J, Gocke C, Baer MR, Duong VH, Wright JJ, Rudek MA, Emadi A, Levis MJ. Prospective Study of Peri-Transplant Use of Sorafenib As Remission Maintenance for FLT3-ITD Patients Undergoing Allogeneic Transplantation Blood. 126: 3164-3164. DOI: 10.1182/Blood.V126.23.3164.3164 |
0.341 |
|
| 2015 |
Gojo I, Beumer JH, Pratz K, Ji J, Wang L, Rudek MA, McDevitt MA, Baer MR, Blackford A, Smith BD, Gore SD, Carraway HE, Showel MM, Levis MJ, DeZern AE, et al. A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Leukemias Blood. 126: 1361-1361. DOI: 10.1182/Blood.V126.23.1361.1361 |
0.354 |
|
| 2014 |
Chen YB, Li S, Lane AA, Connolly C, Del Rio C, Valles B, Curtis M, Ballen K, Cutler C, Dey BR, El-Jawahri A, Fathi AT, Ho VT, Joyce A, McAfee S, ... Rudek M, et al. Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 20: 2042-8. PMID 25239228 DOI: 10.1016/J.Bbmt.2014.09.007 |
0.354 |
|
| 2014 |
Paller CJ, Wissing MD, Mendonca J, Sharma A, Kim E, Kim HS, Kortenhorst MS, Gerber S, Rosen M, Shaikh F, Zahurak ML, Rudek MA, Hammers H, Rudin CM, Carducci MA, et al. Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer. Cancer Medicine. 3: 1322-35. PMID 24989836 DOI: 10.1002/Cam4.289 |
0.393 |
|
| 2014 |
Pillai VC, Parise RA, Christner SM, Rudek MA, Beumer JH, Venkataramanan R. Potential interactions between HIV drugs, ritonavir and efavirenz and anticancer drug, nilotinib--a study in primary cultures of human hepatocytes that is applicable to HIV patients with cancer. Journal of Clinical Pharmacology. 54: 1272-9. PMID 24846165 DOI: 10.1002/Jcph.333 |
0.356 |
|
| 2014 |
De Jesus-Acosta A, Laheru D, Maitra A, Arcaroli J, Rudek MA, Dasari A, Blatchford PJ, Quackenbush K, Messersmith W. A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma. Investigational New Drugs. 32: 739-45. PMID 24668033 DOI: 10.1007/S10637-014-0083-8 |
0.39 |
|
| 2014 |
Karovic S, Wen Y, Karrison TG, Bakris GL, Levine MR, House LK, Wu K, Thomeas V, Rudek MA, Wright JJ, Cohen EE, Fleming GF, Ratain MJ, Maitland ML. Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies. Clinical Pharmacology and Therapeutics. 96: 27-35. PMID 24637941 DOI: 10.1038/Clpt.2014.63 |
0.363 |
|
| 2014 |
Rudek MA, Chang CY, Steadman K, Johnson MD, Desai N, Deeken JF. Combination antiretroviral therapy (cART) component ritonavir significantly alters docetaxel exposure. Cancer Chemotherapy and Pharmacology. 73: 729-36. PMID 24488374 DOI: 10.1007/S00280-014-2399-7 |
0.351 |
|
| 2014 |
Rudek MA, Moore PC, Mitsuyasu RT, Dezube BJ, Aboulafia D, Gerecitano J, Sullivan R, Cianfrocca ME, Henry DH, Ratner L, Haigentz M, Dowlati A, Little RF, Ivy SP, Deeken JF. A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061. Cancer. 120: 1194-202. PMID 24474568 DOI: 10.1002/Cncr.28554 |
0.38 |
|
| 2014 |
Beumer JH, Venkataramanan R, Rudek MA. Pharmacotherapy in cancer patients with HIV/AIDS. Clinical Pharmacology and Therapeutics. 95: 370-2. PMID 24440966 DOI: 10.1038/Clpt.2014.10 |
0.325 |
|
| 2014 |
Peltonen K, Colis L, Liu H, Trivedi R, Moubarek MS, Moore HM, Bai B, Rudek MA, Bieberich CJ, Laiho M. A targeting modality for destruction of RNA polymerase I that possesses anticancer activity. Cancer Cell. 25: 77-90. PMID 24434211 DOI: 10.1016/J.Ccr.2013.12.009 |
0.303 |
|
| 2014 |
Ma H, Nguyen B, Li L, Greenblatt S, Williams A, Zhao M, Levis M, Rudek M, Duffield A, Small D. TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo. Blood. 123: 1525-34. PMID 24408321 DOI: 10.1182/Blood-2013-08-523035 |
0.351 |
|
| 2014 |
Webster MR, Kamat C, Connis N, Zhao M, Weeraratna AT, Rudek MA, Hann CL, Freel Meyers CL. Bisphosphonamidate clodronate prodrug exhibits selective cytotoxic activity against melanoma cell lines. Molecular Cancer Therapeutics. 13: 297-306. PMID 24310621 DOI: 10.1158/1535-7163.Mct-13-0315 |
0.32 |
|
| 2014 |
Rais R, Rojas C, Wozniak K, Wu Y, Zhao M, Tsukamoto T, Rudek MA, Slusher BS. Bioanalytical method for evaluating the pharmacokinetics of the GCP-II inhibitor 2-phosphonomethyl pentanedioic acid (2-PMPA). Journal of Pharmaceutical and Biomedical Analysis. 88: 162-9. PMID 24055700 DOI: 10.1016/J.Jpba.2013.08.028 |
0.311 |
|
| 2014 |
Paller CJ, Rudek MA, Antonarakis ES, Eisenberger MA, Hammers HJ, Zhou XC, Dowling D, King S, Hudock S, Denmeade SR, Wagner WD, Rosner GL, Hudson T, Carducci MA. A phase I trial of muscadine grape skin in men with biochemically recurrent prostate cancer. Journal of Clinical Oncology. 32: 263-263. DOI: 10.1200/Jco.2014.32.4_Suppl.263 |
0.396 |
|
| 2014 |
Connolly RM, Jankowitz RC, Zahnow CA, Zhang Z, Rudek MA, Slater S, Powers P, Jeter S, Brufsky A, Piekarz R, Herman JG, Ahuja N, Somlo G, Garcia AA, Baylin S, et al. Phase 2 study investigating the safety, efficacy, and surrogate biomarkers of response to 5-azacitidine (5-AZA) and entinostat in advanced breast cancer. Journal of Clinical Oncology. 32: 569-569. DOI: 10.1200/Jco.2014.32.15_Suppl.569 |
0.335 |
|
| 2014 |
Tawbi HA, Chu E, Lin Y, Hyman DM, Goel S, Rudek MA, Dowlati A, LoRusso P, Mulkerin D, Chew HK, Kiesel B, Pollice L, Appleman LJ, Puhalla S, Stoller RG, et al. Early phase I study of the PARP inhibitor veliparib (ABT-888) alone or in combination with carboplatin/paclitaxel (CP) in patients with varying degrees of hepatic or renal dysfunction: A study of the NCI-Organ Dysfunction Working Group (ODG). Journal of Clinical Oncology. 32: 2572-2572. DOI: 10.1200/Jco.2014.32.15_Suppl.2572 |
0.342 |
|
| 2014 |
Chen Y, Shuli L, Andrew LA, Connolly C, Rio CD, Valles B, Curtis M, Ballen KK, Cutler CS, Dey BR, El-Jawahri A, Fathi AT, Ho VT, Joyce A, McAfee SL, ... Rudek MA, et al. Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Patients with FLT3-ITD AML Blood. 124: 671-671. DOI: 10.1182/Blood.V124.21.671.671 |
0.392 |
|
| 2014 |
Ramos JC, Sparano J, Moore P, Lee JY, Rudek MA, Ambinder RF, Cesarman E, Noy A, Mitsuyasu RT. AMC075: The Combination of Vorinostat with Chemotherapy and Rituximab Is Tolerable and Feasible in HIV-Related B-Cell Non-Hodgkin’s Lymphoma with High-Risk Features Blood. 124: 4473-4473. DOI: 10.1182/Blood.V124.21.4473.4473 |
0.338 |
|
| 2013 |
Bardia A, Blackford AL, Lin J, Armstrong AJ, King S, Rudek MA, Yegnasubramanian ST, Carducci MA. A prostate cancer clinical trials consortium trial of disulfiram (D) in men with nonmetastatic recurrent prostate cancer (PCa). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 219. PMID 28137035 DOI: 10.1200/Jco.2013.31.6_Suppl.219 |
0.318 |
|
| 2013 |
Schweizer MT, Lin J, Blackford A, Bardia A, King S, Armstrong AJ, Rudek MA, Yegnasubramanian S, Carducci MA. Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer. Prostate Cancer and Prostatic Diseases. 16: 357-61. PMID 23958896 DOI: 10.1038/Pcan.2013.28 |
0.326 |
|
| 2013 |
Pillai VC, Venkataramanan R, Parise RA, Christner SM, Gramignoli R, Strom SC, Rudek MA, Beumer JH. Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 1843-51. PMID 23913028 DOI: 10.1124/Dmd.113.052100 |
0.361 |
|
| 2013 |
Stearns V, Jacobs LK, Fackler M, Tsangaris TN, Rudek MA, Higgins M, Lange J, Cheng Z, Slater SA, Jeter SC, Powers P, Briest S, Chao C, Yoshizawa C, Sugar E, et al. Biomarker modulation following short-term vorinostat in women with newly diagnosed primary breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 4008-16. PMID 23719261 DOI: 10.1158/1078-0432.Ccr-13-0033 |
0.326 |
|
| 2013 |
Shibata SI, Chung V, Synold TW, Longmate JA, Suttle AB, Ottesen LH, Lenz HJ, Kummar S, Harvey RD, Hamilton AL, O'Neil BH, Sarantopoulos J, LoRusso P, Rudek MA, Dowlati A, et al. Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 3631-9. PMID 23653147 DOI: 10.1158/1078-0432.Ccr-12-3214 |
0.367 |
|
| 2013 |
Grossman R, Tyler B, Rudek MA, Kim E, Zadnik P, Khan U, Blakeley JO, Pathak AP, Brem H. Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model. Cancer Chemotherapy and Pharmacology. 72: 93-100. PMID 23649683 DOI: 10.1007/S00280-013-2172-3 |
0.321 |
|
| 2013 |
Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA, Pierce S, Daver N, Garcia-Manero G, Faderl S, Nazha A, Konopleva M, Borthakur G, Burger J, Kadia T, et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood. 121: 4655-62. PMID 23613521 DOI: 10.1182/Blood-2013-01-480228 |
0.379 |
|
| 2013 |
Rudek MA, Connolly RM, Hoskins JM, Garrett-Mayer E, Jeter SC, Armstrong DK, Fetting JH, Stearns V, Wright LA, Zhao M, Watkins SP, McLeod HL, Davidson NE, Wolff AC. Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer. Breast Cancer Research and Treatment. 139: 135-43. PMID 23588952 DOI: 10.1007/S10549-013-2516-Z |
0.388 |
|
| 2013 |
Dutta NK, Pinn ML, Zhao M, Rudek MA, Karakousis PC. Thioridazine lacks bactericidal activity in an animal model of extracellular tuberculosis. The Journal of Antimicrobial Chemotherapy. 68: 1327-30. PMID 23463208 DOI: 10.1093/Jac/Dkt037 |
0.326 |
|
| 2013 |
Antonarakis ES, Heath EI, Smith DC, Rathkopf D, Blackford AL, Danila DC, King S, Frost A, Ajiboye AS, Zhao M, Mendonca J, Kachhap SK, Rudek MA, Carducci MA. Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer. The Oncologist. 18: 163-73. PMID 23340005 DOI: 10.1634/Theoncologist.2012-314 |
0.376 |
|
| 2013 |
Azad N, Dasari A, Arcaroli J, Taylor GE, Laheru DA, Carducci MA, McManus M, Quackenbush K, Wright JJ, Hidalgo M, Diaz LA, Donehower RC, Zhao M, Rudek MA, Messersmith WA. Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer. Investigational New Drugs. 31: 345-54. PMID 22615057 DOI: 10.1007/S10637-012-9820-Z |
0.409 |
|
| 2013 |
Connolly RM, Jankowitz RC, Zahnow CA, Zhang Z, Rudek MA, Jeter SC, Slater S, Powers P, Wolff AC, Fetting J, Brufsky AM, Piekarz R, Ahuja N, Somlo G, Garcia A, et al. Abstract 4666: A phase 2 study investigating the safety, efficacy and surrogate biomarkers of response of 5-azacitidine (5-AZA) andentinostat (MS-275) in patients with triple-negative advanced breast cancer. Cancer Research. 73: 4666-4666. DOI: 10.1158/1538-7445.Am2013-4666 |
0.391 |
|
| 2013 |
Wilky BA, Rudek M, Laheru D, Cosgrove D, Donehower R, Nelkin B, Ball D, Doyle LA, Chen H, Ye X, Azad N. Abstract B74: A Phase I trial of vertical inhibition of IGF signaling using IMC-A12, an IGF1-R inhibitor, and AZD6244, a MEK 1/2 inhibitor, in patients with advanced solid tumors. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B74 |
0.431 |
|
| 2013 |
Azad N, Ball D, Sherman S, Rudek M, Falchook G, Nelkin B, Janku F, Papadopoulos N, O'Conner A, Ahmed S, Wilky B, Markus S, Gong J, Cosgrove D, Zahurak M, et al. Abstract B279: A phase I study determining the safety and tolerability of combination therapy with Pazopanib (P), a VEGFR/PDGFR/Raf inhibitor, and GSK1120212 (Trametinib: T), a MEK inhibitor, in advanced solid tumors with expansion cohorts in advanced differentiated thyroid cancer (DTC), cholangiocarcinoma (ChCA), and soft tissue sarcoma (STS). Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B279 |
0.411 |
|
| 2012 |
Chun YS, Bisht S, Chenna V, Pramanik D, Yoshida T, Hong SM, de Wilde RF, Zhang Z, Huso DL, Zhao M, Rudek MA, Stearns V, Maitra A, Sukumar S. Intraductal administration of a polymeric nanoparticle formulation of curcumin (NanoCurc) significantly attenuates incidence of mammary tumors in a rodent chemical carcinogenesis model: Implications for breast cancer chemoprevention in at-risk populations. Carcinogenesis. 33: 2242-9. PMID 22831956 DOI: 10.1093/Carcin/Bgs248 |
0.39 |
|
| 2012 |
Deeken JF, Tjen-A-Looi A, Rudek MA, Okuliar C, Young M, Little RF, Dezube BJ. The rising challenge of non-AIDS-defining cancers in HIV-infected patients. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 55: 1228-35. PMID 22776851 DOI: 10.1093/Cid/Cis613 |
0.307 |
|
| 2012 |
Karp JE, Garrett-Mayer E, Estey EH, Rudek MA, Douglas Smith B, Greer JM, Michelle Drye D, Mackey K, Dorcy KS, Gore SD, Levis MJ, McDevitt MA, Carraway HE, Pratz KW, Gladstone DE, et al. Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia Haematologica. 97: 1736-1742. PMID 22733022 DOI: 10.3324/Haematol.2012.062539 |
0.309 |
|
| 2012 |
Grossman R, Rudek MA, Brastianos H, Zadnik P, Brem H, Tyler B, Blakeley JO. The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas. Cancer Chemotherapy and Pharmacology. 70: 129-39. PMID 22644796 DOI: 10.1007/S00280-012-1867-1 |
0.317 |
|
| 2012 |
Laheru D, Shah P, Rajeshkumar NV, McAllister F, Taylor G, Goldsweig H, Le DT, Donehower R, Jimeno A, Linden S, Zhao M, Song D, Rudek MA, Hidalgo M. Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer. Investigational New Drugs. 30: 2391-9. PMID 22547163 DOI: 10.1007/S10637-012-9818-6 |
0.378 |
|
| 2012 |
LoRusso PM, Venkatakrishnan K, Ramanathan RK, Sarantopoulos J, Mulkerin D, Shibata SI, Hamilton A, Dowlati A, Mani S, Rudek MA, Takimoto CH, Neuwirth R, Esseltine DL, Ivy P. Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 2954-63. PMID 22394984 DOI: 10.1158/1078-0432.Ccr-11-2873 |
0.369 |
|
| 2012 |
Gilbert J, Rudek MA, Higgins MJ, Zhao M, Bienvenu S, Tsottles N, Wahl R, Forastiere A, Gillison M. A phase I trial of erlotinib and concurrent chemoradiotherapy for stage III and IV (M0) squamous cell carcinoma of the head and neck Clinical Cancer Research. 18: 1735-1742. PMID 22271880 DOI: 10.1158/1078-0432.Ccr-11-2544 |
0.394 |
|
| 2012 |
Rais R, Zhao M, He P, Xu L, Deeken JF, Rudek MA. Quantitation of unbound sunitinib and its metabolite N-desethyl sunitinib (SU12662) in human plasma by equilibrium dialysis and liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study. Biomedical Chromatography : Bmc. 26: 1315-24. PMID 22259028 DOI: 10.1002/Bmc.2697 |
0.31 |
|
| 2012 |
Pili R, Salumbides B, Zhao M, Altiok S, Qian D, Zwiebel J, Carducci MA, Rudek MA. Phase i study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours British Journal of Cancer. 106: 77-84. PMID 22134508 DOI: 10.1038/Bjc.2011.527 |
0.416 |
|
| 2012 |
Villarroel MC, Pratz KW, Xu L, Wright JJ, Smith BD, Rudek MA. Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients. Investigational New Drugs. 30: 2096-102. PMID 22089297 DOI: 10.1007/S10637-011-9767-5 |
0.385 |
|
| 2012 |
Chenna V, Hu C, Pramanik D, Aftab BT, Karikari C, Campbell NR, Hong SM, Zhao M, Rudek MA, Khan SR, Rudin CM, Maitra A. A polymeric nanoparticle encapsulated small-molecule inhibitor of Hedgehog signaling (NanoHHI) bypasses secondary mutational resistance to Smoothened antagonists. Molecular Cancer Therapeutics. 11: 165-73. PMID 22027695 DOI: 10.1158/1535-7163.Mct-11-0341 |
0.326 |
|
| 2012 |
Ahmed SR, Azad NS, Ball DW, Rudek MA, Nelkin B, Cosgrove D, Gong J, Finkelstein D, Zahurak M, Janku F, Downs M, O'Connor A, Markus S, Carducci MA, Sherman SI, et al. A phase I study determining the safety and tolerability of combination therapy with pazopanib, a VEGFR/PDGFR/raf inhibitor, and GSK1120212, a MEK inhibitor, in advanced solid tumors enriched with patients with advanced differentiated thyroid cancer. Journal of Clinical Oncology. 30: TPS3117-TPS3117. DOI: 10.1200/Jco.2012.30.15_Suppl.Tps3117 |
0.394 |
|
| 2012 |
Deeken JF, Rudek MA, Moore PC, Aboulafia D, Sullivan R, Gerecitano J, Cianfrocca M, Henry D, Ratner L, Dezube B, Mosby K, Tibbals M, Little RF, Ivy SP, Mitsuyasu RT. A phase 1/PK study of Sunitinib with highly active antiretroviral therapy (HAART) in HIV+ patients with solid tumors: AIDS malignancy consortium study 061 Infectious Agents and Cancer. 7: 1-2. DOI: 10.1186/1750-9378-7-S1-O15 |
0.416 |
|
| 2012 |
Antonarakis ES, Heath EI, Smith DC, Rathkopf D, Blackford AL, Danila DC, King S, Frost A, Ajiboye AS, Zhao M, Mendonca J, Kachhap SK, Rudek MA, Carducci MA. Abstract LB-224: A randomized phase 2 study of two doses of itraconazole in men with metastatic castration-resistant prostate cancer (mCRPC) Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-224 |
0.374 |
|
| 2012 |
Rasheed ZA, Rajeshkumar N, Jung C, Huang A, Agarwal J, Oliviero E, Rudek M, Zhao M, He P, DeJesus-Acosta A, Laheru D, Maitra A, Parhami F, Matsui W. Abstract 3494: Liver X receptor activation represents a novel strategy to block Hedgehog signaling in pancreatic adenocarcinoma and enhance the antitumor effect of gemcitabine Cancer Research. 72: 3494-3494. DOI: 10.1158/1538-7445.Am2012-3494 |
0.374 |
|
| 2011 |
Connolly RM, Rudek MA, Mc Leod HL, Garrett-Mayer E, Jeter SC, Wright LA, Stearns V, Armstrong DK, Fetting JH, Watkins SP, Davidson NE, Wolff AC. A phase II pharmacokinetic/pharmacogenetic (PK/PG) study using fixed-dose capecitabine in metastatic breast cancer (MBC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 1067. PMID 28020631 DOI: 10.1200/Jco.2011.29.15_Suppl.1067 |
0.359 |
|
| 2011 |
Dasari A, Rudek MA, Arcaroli J, Powell RW, Carducci MA, Laheru D, Wright JJ, Hidalgo M, Messersmith WA, Azad NS. Tolerance of full-dose sorafenib (S) combined with irinotecan (I; weekly, two on, one off) and cetuximab (C) in previously treated patients with advanced colorectal cancer (CRC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 522. PMID 27985761 DOI: 10.1200/Jco.2011.29.4_Suppl.522 |
0.36 |
|
| 2011 |
Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, Coleman B, Sebree R, Rodgers K, Hooker CM, Franco N, Lee B, Tsai S, Delgado IE, Rudek MA, Belinsky SA, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discovery. 1: 598-607. PMID 22586682 DOI: 10.1158/2159-8290.Cd-11-0214 |
0.362 |
|
| 2011 |
Stearns V, Mori T, Jacobs LK, Khouri NF, Gabrielson E, Yoshida T, Kominsky SL, Huso DL, Jeter S, Powers P, Tarpinian K, Brown RJ, Lange JR, Rudek MA, Zhang Z, et al. Preclinical and clinical evaluation of intraductally administered agents in early breast cancer. Science Translational Medicine. 3: 106ra108. PMID 22030751 DOI: 10.1126/Scitranslmed.3002368 |
0.386 |
|
| 2011 |
Webster MR, Zhao M, Rudek MA, Hann CL, Freel Meyers CL. Bisphosphonamidate clodronate prodrug exhibits potent anticancer activity in non-small-cell lung cancer cells. Journal of Medicinal Chemistry. 54: 6647-56. PMID 21863853 DOI: 10.1021/Jm200521A |
0.322 |
|
| 2011 |
Tyler B, Wadsworth S, Recinos V, Mehta V, Vellimana A, Li K, Rosenblatt J, Do H, Gallia GL, Siu IM, Wicks RT, Rudek MA, Zhao M, Brem H. Local delivery of rapamycin: a toxicity and efficacy study in an experimental malignant glioma model in rats. Neuro-Oncology. 13: 700-9. PMID 21727209 DOI: 10.1093/Neuonc/Nor050 |
0.382 |
|
| 2011 |
Rudek MA, Flexner C, Ambinder RF. Use of antineoplastic agents in patients with cancer who have HIV/AIDS. The Lancet. Oncology. 12: 905-12. PMID 21570912 DOI: 10.1016/S1470-2045(11)70056-0 |
0.319 |
|
| 2011 |
Rudek MA, New P, Mikkelsen T, Phuphanich S, Alavi JB, Nabors LB, Piantadosi S, Fisher JD, Grossman SA. Phase I and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomas. Journal of Neuro-Oncology. 105: 375-81. PMID 21547395 DOI: 10.1007/S11060-011-0602-9 |
0.399 |
|
| 2011 |
Connolly RM, Rudek MA, Garrett-Mayer E, Jeter SC, Donehower MG, Wright LA, Zhao M, Fetting JH, Emens LA, Stearns V, Davidson NE, Baker SD, Wolff AC. Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer. Breast Cancer Research and Treatment. 127: 153-62. PMID 21350820 DOI: 10.1007/S10549-011-1413-6 |
0.417 |
|
| 2011 |
Karp JE, Smith BD, Resar LS, Greer JM, Blackford A, Zhao M, Moton-Nelson D, Alino K, Levis MJ, Gore SD, Joseph B, Carraway H, McDevitt MA, Bagain L, Mackey K, ... ... Rudek MA, et al. Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood. 117: 3302-10. PMID 21239698 DOI: 10.1182/Blood-2010-09-310862 |
0.361 |
|
| 2011 |
Cianfrocca M, Lee S, Von Roenn J, Rudek MA, Dezube BJ, Krown SE, Sparano JA. Pilot study evaluating the interaction between paclitaxel and protease inhibitors in patients with human immunodeficiency virus-associated Kaposi's sarcoma: an Eastern Cooperative Oncology Group (ECOG) and AIDS Malignancy Consortium (AMC) trial. Cancer Chemotherapy and Pharmacology. 68: 827-33. PMID 21207228 DOI: 10.1007/S00280-010-1509-4 |
0.336 |
|
| 2011 |
Fracasso PM, Williams KJ, Chen RC, Picus J, Ma CX, Ellis MJ, Tan BR, Pluard TJ, Adkins DR, Naughton MJ, Rader JS, Arquette MA, Fleshman JW, Creekmore AN, Goodner SA, ... ... Rudek MA, et al. A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. Cancer Chemotherapy and Pharmacology. 67: 1225-37. PMID 20694727 DOI: 10.1007/S00280-010-1410-1 |
0.4 |
|
| 2011 |
Smith BD, Jones RJ, Cho E, Kowalski J, Karp JE, Gore SD, Vala M, Meade B, Baker SD, Zhao M, Piantadosi S, Zhang Z, Blumenthal G, Warlick ED, Brodsky RA, ... ... Rudek MA, et al. Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF. Leukemia Research. 35: 87-94. PMID 20598742 DOI: 10.1016/J.Leukres.2010.06.001 |
0.343 |
|
| 2011 |
Weekes CD, Nallapareddy S, Rudek MA, Norris-Kirby A, Laheru D, Jimeno A, Donehower RC, Murphy KM, Hidalgo M, Baker SD, Messersmith WA. Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer. Investigational New Drugs. 29: 1057-65. PMID 20306339 DOI: 10.1007/S10637-010-9413-7 |
0.381 |
|
| 2010 |
Messersmith WA, Jimeno A, Jacene H, Zhao M, Kulesza P, Laheru DA, Kahn Y, Spira A, Dancey J, Iacobuzio-Donahue C, Donehower RC, Carducci M, Rudek MA, Hidalgo M. Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. Clinical Colorectal Cancer. 9: 297-304. PMID 21208844 DOI: 10.3816/Ccc.2010.N.043 |
0.386 |
|
| 2010 |
Ma WW, Herman JM, Jimeno A, Laheru D, Messersmith WA, Wolfgang CL, Cameron JL, Pawlik TM, Donehower RC, Rudek MA, Hidalgo M. A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer. Translational Oncology. 3: 373-9. PMID 21151476 DOI: 10.1593/Tlo.10196 |
0.408 |
|
| 2010 |
Garrido-Laguna I, Tan AC, Uson M, Angenendt M, Ma WW, Villaroel MC, Zhao M, Rajeshkumar NV, Jimeno A, Donehower R, Iacobuzio-Donahue C, Barrett M, Rudek MA, Rubio-Viqueira B, Laheru D, et al. Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer British Journal of Cancer. 103: 649-655. PMID 20664591 DOI: 10.1038/Sj.Bjc.6605819 |
0.399 |
|
| 2010 |
Bisht S, Mizuma M, Feldmann G, Ottenhof NA, Hong SM, Pramanik D, Chenna V, Karikari C, Sharma R, Goggins MG, Rudek MA, Ravi R, Maitra A, Maitra A. Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer. Molecular Cancer Therapeutics. 9: 2255-64. PMID 20647339 DOI: 10.1158/1535-7163.Mct-10-0172 |
0.393 |
|
| 2010 |
Hammers HJ, Verheul HM, Salumbides B, Sharma R, Rudek M, Jaspers J, Shah P, Ellis L, Shen L, Paesante S, Dykema K, Furge K, Teh BT, Netto G, Pili R. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Molecular Cancer Therapeutics. 9: 1525-35. PMID 20501804 DOI: 10.1158/1535-7163.Mct-09-1106 |
0.359 |
|
| 2010 |
Armstrong AJ, Netto GJ, Rudek MA, Halabi S, Wood DP, Creel PA, Mundy K, Davis SL, Wang T, Albadine R, Schultz L, Partin AW, Jimeno A, Fedor H, Febbo PG, et al. A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 3057-66. PMID 20501622 DOI: 10.1158/1078-0432.Ccr-10-0124 |
0.356 |
|
| 2010 |
Reinhardt S, Zhao M, Mnatsakanyan A, Xu L, Ricklis RM, Chen A, Karp JE, Rudek MA. A rapid and sensitive method for determination of veliparib (ABT-888), in human plasma, bone marrow cells and supernatant by using LC/MS/MS. Journal of Pharmaceutical and Biomedical Analysis. 52: 122-8. PMID 20071126 DOI: 10.1016/J.Jpba.2009.12.015 |
0.307 |
|
| 2010 |
Altiok S, Mezzadra H, Jagannath S, Tsottles N, Rudek MA, Abdallah N, Berman D, Forastiere A, Gibson MK. A novel pharmacodynamic approach to assess and predict tumor response to the epidermal growth factor receptor inhibitor gefitinib in patients with esophageal cancer. International Journal of Oncology. 36: 19-27. PMID 19956829 DOI: 10.3892/Ijo-00000471 |
0.386 |
|
| 2010 |
Tsimberidou AM, Rudek MA, Hong D, Ng CS, Blair J, Goldsweig H, Kurzrock R. Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors. Cancer Chemotherapy and Pharmacology. 65: 235-41. PMID 19484470 DOI: 10.1007/S00280-009-1027-4 |
0.305 |
|
| 2010 |
Juergens RA, Gibson MK, Yang SC, Brock M, Heitmiller R, Tsottles N, Rudek MA, Canto M, Kleinberg L, Forastiere AA. Phase II study of neoadjuvant and adjuvant gefitinib (G) with neoadjuvant chemoradiotherapy (CRT) in operable esophageal adenocarcinoma (EAC). Journal of Clinical Oncology. 28. DOI: 10.1200/Jco.2010.28.15_Suppl.E14532 |
0.331 |
|
| 2010 |
Pratz KW, Kaufmann SH, Litzow MR, Ji J, Chen A, Rudek MA, Karp JE. Phase I Trial of the Oral Poly (ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888, V) Combined Wtih Topoecan (T) and Carboplatin (C) for Adults with Relapsed and Refractory Acute Leukemias, Blood. 118: 3634-3634. DOI: 10.1182/Blood.V118.21.3634.3634 |
0.347 |
|
| 2010 |
Venkatakrishnan K, Ramanathan RK, Sarantopoulos J, Mulkerin DL, Shibata SI, Hamilton A, Dowlati A, Mani S, Rudek MA, Ivy P, Takimoto CH, Neuwirth R, Parasuraman S, LoRusso PM. Pharmacokinetics and Safety of Bortezomib In Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Results of the Phase 1 National Cancer Institute Organ Dysfunction Working Group Study NCI 6432 Blood. 116: 3975-3975. DOI: 10.1182/Blood.V116.21.3975.3975 |
0.337 |
|
| 2010 |
Sun W, Liu Y, Glazer CA, Shao C, Bhan S, Demokan S, Zhao M, Rudek MA, Ha PK, Califano JA. Abstract 63:TKTL1is activated by promoter hypomethylation and contributes to head and neck squamous cell carcinoma carcinogenesis via increased aerobic glycolysis and HIF1-alpha stabilization Cancer Research. 70: 63-63. DOI: 10.1158/1538-7445.Am10-63 |
0.314 |
|
| 2010 |
Hammers HJ, Verheul H, Salumbides B, Sharma R, Jaspers J, Rudek M, Netto G, Pili R. Abstract 388: Epithelial to mesenchymal transition is associated with acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study Cancer Research. 70: 388-388. DOI: 10.1158/1538-7445.Am10-388 |
0.371 |
|
| 2009 |
Jacobs LK, Khouri N, Jeter S, Powers P, Rudek M, Gabrielson E, Zhang Z, Sukumar S, Tsangaris T, Stearns V. A phase I study assessing the feasibility and safety of intraductal pegylated liposomal doxorubicin (PLD) in women with breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e11506. PMID 27964594 DOI: 10.1200/Jco.2009.27.15_Suppl.E11506 |
0.334 |
|
| 2009 |
Bao T, Slater SA, Blackford A, Jeter SC, Wright L, Rudek MA, Desta Z, Stearns V. Effect of simvastatin on the pharmacokinetics of anastrozole. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1517. PMID 27964328 DOI: 10.1200/Jco.2009.27.15_Suppl.1517 |
0.325 |
|
| 2009 |
Garrido-Laguna I, Rudek M, Tan A, Uson M, Iacobuzio-Donahue C, Angenendt M, Jimeno A, Laheru D, Barret M, Hidalgo M. Preclinical identification of biomarkers of response to mTOR inhibitors and subsequent application in a phase II trial of sirolimus in pancreatic cancer patients refractory to gemcitabine. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4612. PMID 27964189 DOI: 10.1200/Jco.2009.27.15_Suppl.4612 |
0.38 |
|
| 2009 |
Netto G, Armstrong A, Wood D, Creel P, Partin A, Jimeno A, Rudek M, George D, Gurganus R, Carducci MA. Pharmacodynamic (PD) study of pre-prostatectomy rapamycin in men with advanced localized prostate cancer (PC): A DOD Prostate Cancer Clinical Trials Consortium Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5001. PMID 27962897 DOI: 10.1200/Jco.2009.27.15_Suppl.5001 |
0.35 |
|
| 2009 |
Juergens RA, Vendetti F, Coleman B, Sebree RS, Rudek MA, Belinsky S, Brock M, Herman J, Baylin S, Rudin CM. Interim analysis of a phase II trial of 5-azacitidine (5AC) and entinostat (SNDX-275) in relapsed advanced lung cancer (NSCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 8055. PMID 27962870 DOI: 10.1200/Jco.2009.27.15_Suppl.8055 |
0.34 |
|
| 2009 |
Pratz KW, Cho E, Karp J, Levis M, Zhao M, Rudek M, Wright J, Smith BD. Phase I dose escalation trial of sorafenib as a single agent for adults with relapsed and refractory acute leukemias. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 7065. PMID 27961441 DOI: 10.1200/Jco.2009.27.15_Suppl.7065 |
0.338 |
|
| 2009 |
Lin J, Gilbert J, Rudek MA, Zwiebel JA, Gore S, Jiemjit A, Zhao M, Baker SD, Ambinder RF, Herman JG, Donehower RC, Carducci MA. A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 6241-9. PMID 19789320 DOI: 10.1158/1078-0432.Ccr-09-0567 |
0.385 |
|
| 2009 |
Jimeno A, Chan A, Cusatis G, Zhang X, Wheelhouse J, Solomon A, Chan F, Zhao M, Cosenza SC, Ramana Reddy MV, Rudek MA, Kulesza P, Donehower RC, Reddy EP, Hidalgo M. Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay. Oncogene. 28: 610-8. PMID 19029951 DOI: 10.1038/Onc.2008.424 |
0.362 |
|
| 2009 |
Durrant D, Corwin F, Simoni D, Zhao M, Rudek MA, Salloum FN, Kukreja RC, Fatouros PP, Lee RM. cis-3, 4', 5-Trimethoxy-3'-aminostilbene disrupts tumor vascular perfusion without damaging normal organ perfusion. Cancer Chemotherapy and Pharmacology. 63: 191-200. PMID 18365199 DOI: 10.1007/S00280-008-0726-6 |
0.323 |
|
| 2009 |
Maitra A, Rajeshkumar NV, Rudek M, Garrido‐Laguna I, Laheru D, Iglesias J, Desai N, Hoff DDV, Hidalgo M. Abstract C246: nab®‐paclitaxel targets tumor stroma and results, combined with gemcitabine, in high efficacy against pancreatic cancer models Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-C246 |
0.382 |
|
| 2008 |
Tsimberidou AM, Rudek MA, Hong DS, Ng CS, Blair J, Goldsweig H, Kurzrock R. Phase I first-in-human study of s-trans, trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 3536. PMID 27949793 DOI: 10.1200/Jco.2008.26.15_Suppl.3536 |
0.324 |
|
| 2008 |
Bisht S, Feldmann G, Koorstra JB, Mullendore M, Alvarez H, Karikari C, Rudek MA, Lee CK, Maitra A, Maitra A. In vivo characterization of a polymeric nanoparticle platform with potential oral drug delivery capabilities. Molecular Cancer Therapeutics. 7: 3878-88. PMID 19074860 DOI: 10.1158/1535-7163.Mct-08-0476 |
0.34 |
|
| 2008 |
Jimeno A, Li J, Messersmith WA, Laheru D, Rudek MA, Maniar M, Hidalgo M, Baker SD, Donehower RC. Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5504-10. PMID 18955447 DOI: 10.1200/Jco.2008.17.9788 |
0.373 |
|
| 2008 |
Laheru D, Croghan G, Bukowski R, Rudek M, Messersmith W, Erlichman C, Pelley R, Jimeno A, Donehower R, Boni J, Abbas R, Martins P, Zacharchuk C, Hidalgo M. A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 5602-9. PMID 18765554 DOI: 10.1158/1078-0432.Ccr-08-0433 |
0.419 |
|
| 2008 |
Jimeno A, Rudek MA, Kulesza P, Ma WW, Wheelhouse J, Howard A, Khan Y, Zhao M, Jacene H, Messersmith WA, Laheru D, Donehower RC, Garrett-Mayer E, Baker SD, Hidalgo M. Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 4172-9. PMID 18757332 DOI: 10.1200/Jco.2008.16.2347 |
0.362 |
|
| 2008 |
Zhao M, He P, Xu L, Hidalgo M, Laheru D, Rudek MA. Determination of salirasib (S-trans,trans-farnesylthiosalicylic acid) in human plasma using liquid chromatography-tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 869: 142-5. PMID 18534927 DOI: 10.1016/J.Jchromb.2008.05.028 |
0.307 |
|
| 2008 |
Jimeno A, Rudek MA, Purcell T, Laheru DA, Messersmith WA, Dancey J, Carducci MA, Baker SD, Hidalgo M, Donehower RC. Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. Cancer Chemotherapy and Pharmacology. 61: 423-33. PMID 17429623 DOI: 10.1007/S00280-007-0485-9 |
0.404 |
|
| 2008 |
Juergens RA, Vendetti F, Coleman B, Sebree RS, Rudek MA, Belinsky SA, Brock MV, Herman JG, Baylin SB, Rudin CM. Phase I trial of 5-azacitidine (5AC) and SNDX-275 in advanced lung cancer (NSCLC) Journal of Clinical Oncology. 26: 19036-19036. DOI: 10.1200/Jco.2008.26.15_Suppl.19036 |
0.393 |
|
| 2008 |
Resar L, Hillion J, Alino K, Rudek M, Karp J. Flavopiridol Down-Regulates Genes Involved in Cell Cycle Regulation and Tumor Progression in Adults with Refractory or Poor-Risk Acute Leukemia. Blood. 112: 953-953. DOI: 10.1182/Blood.V112.11.953.953 |
0.333 |
|
| 2008 |
Sukumar S, Stearns V, Khouri N, Jacobs L, Jeter S, Powers P, Rudek M, Gabrielson E, Zhang Z, Tsangaris T. Abstract CN13-03: Intraductal route of breast cancer prevention and therapy: from preclinical studies to Phase I trials Cancer Prevention Research. 1. DOI: 10.1158/1940-6207.Prev-08-Cn13-03 |
0.344 |
|
| 2008 |
Ma W, Herman JM, Laheru D, Messersmith W, Jimeno A, Rudek M, Khan Y, Howard A, Donehower R, Hidalgo M. A Phase I Tolerability and Pharmacokinetic Study of Adjuvant Erlotinib (E) and Capecitabine (Cap) with Concurrent Radiation (RT) in Resected Pancreatic Cancer (PanCa) International Journal of Radiation Oncology Biology Physics. 72. DOI: 10.1016/J.Ijrobp.2008.06.429 |
0.309 |
|
| 2007 |
Li J, Zhao M, Jimeno A, He P, Ramana Reddy MV, Hidalgo M, Donehower RC, Rudek MA. Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ON 01910.Na, a mitotic progression modulator, in human plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 856: 198-204. PMID 17588831 DOI: 10.1016/J.Jchromb.2007.05.047 |
0.308 |
|
| 2007 |
Messersmith WA, Rudek MA, Baker SD, Zhao M, Collins C, Colevas AD, Donehower RC, Carducci MA, Wolff AC. Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours. European Journal of Cancer (Oxford, England : 1990). 43: 78-86. PMID 17084620 DOI: 10.1016/J.Ejca.2006.09.006 |
0.382 |
|
| 2007 |
Zhao M, Rudek MA, Mnasakanyan A, Hartke C, Pili R, Baker SD. A liquid chromatography/tandem mass spectrometry assay to quantitate MS-275 in human plasma. Journal of Pharmaceutical and Biomedical Analysis. 43: 784-7. PMID 16971082 DOI: 10.1016/J.Jpba.2006.08.006 |
0.309 |
|
| 2007 |
Jimeno A, Chan A, Zhang X, Wheelhouse J, Solomon A, Cosenza SC, Reddy M, Rudek M, Kulesza P, Reddy E, Hidalgo M. Evaluation of ON 01910.Na, a novel modulator of polo-like kinase 1 (Plk1) pathway, and development of a cyclin-B1-based predictive assay in pancreatic cancer Journal of Clinical Oncology. 25: 3569-3569. DOI: 10.1200/Jco.2007.25.18_Suppl.3569 |
0.337 |
|
| 2007 |
Gibson MK, Mezzadra H, Kleinberg L, Jagannath S, Brock M, Abdallah N, Rudek M, Berman D, Forastiere A, Altiok S. Predicting and monitoring tumor response to epidermal growth factor receptor inhibitor gefitinib in patients with locally advanced esophageal adenocarcinoma Journal of Clinical Oncology. 25: 14112-14112. DOI: 10.1200/Jco.2007.25.18_Suppl.14112 |
0.331 |
|
| 2006 |
Gore SD, Baylin S, Sugar E, Carraway H, Miller CB, Carducci M, Grever M, Galm O, Dauses T, Karp JE, Rudek MA, Zhao M, Smith BD, Manning J, Jiemjit A, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Research. 66: 6361-9. PMID 16778214 DOI: 10.1158/0008-5472.Can-06-0080 |
0.334 |
|
| 2006 |
Kulesza P, Brahmer JR, Jimeno A, Baker SD, Spitz A, Li J, Rudek MA, Messersmith WA, Hidalgo M. Evaluation of gefitinib biological effects in patients with solid tumors amenable to sequential biopsies—Final results Journal of Clinical Oncology. 24: 3090-3090. DOI: 10.1200/Jco.2006.24.18_Suppl.3090 |
0.312 |
|
| 2006 |
Pili R, Rudek M, Altiok S, Qian D, Zhao M, Donehower R, Anderson A, Halter M, McFarland H, Zwiebel J, Carducci M. Phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor MS-275 in combination with 13-cis retinoic acid in patients with advanced solid tumors Journal of Clinical Oncology. 24: 3055-3055. DOI: 10.1200/Jco.2006.24.18_Suppl.3055 |
0.378 |
|
| 2006 |
LI J, RUDEK M, VENITZ J, REED E, FIGG W, KARLSSON M. PI-51Population pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer Clinical Pharmacology & Therapeutics. 79: P20-P20. DOI: 10.1016/J.Clpt.2005.12.072 |
0.486 |
|
| 2005 |
Rudek MA, Zhao M, Smith NF, Robey RW, He P, Hallur G, Khan S, Hidalgo M, Jimeno A, Colevas AD, Messersmith WA, Wolff AC, Baker SD. In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 8503-11. PMID 16322314 DOI: 10.1158/1078-0432.Ccr-05-1037 |
0.311 |
|
| 2005 |
Rudek MA, Zhao M, He P, Hartke C, Gilbert J, Gore SD, Carducci MA, Baker SD. Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 3906-11. PMID 15851763 DOI: 10.1200/Jco.2005.07.450 |
0.35 |
|
| 2005 |
Rudek MA, Hartke C, Zabelina Y, Zhao M, New P, Baker SD. A sensitive method for determination of COL-3, a chemically modified tetracycline, in human plasma using high-performance liquid chromatography and ultraviolet detection. Journal of Pharmaceutical and Biomedical Analysis. 37: 751-6. PMID 15797797 DOI: 10.1016/J.Jpba.2004.10.052 |
0.311 |
|
| 2004 |
Zhao M, Rudek MA, He P, Hartke C, Gore S, Carducci MA, Baker SD. Quantification of 5-azacytidine in plasma by electrospray tandem mass spectrometry coupled with high-performance liquid chromatography. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 813: 81-8. PMID 15556519 DOI: 10.1016/J.Jchromb.2004.09.012 |
0.309 |
|
| 2004 |
Rudek MA, Zabelina Y, Zhao M, Wolff AC, Baker SD. A method for determination of dimethyl benzoylphenyl urea (BPU) in human plasma by using LC/UV. Biomedical Chromatography : Bmc. 18: 282-7. PMID 15236435 DOI: 10.1002/Bmc.314 |
0.367 |
|
| 2004 |
Rudek MA, Sparreboom A, Garrett-Mayer ES, Armstrong DK, Wolff AC, Verweij J, Baker SD. Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. European Journal of Cancer (Oxford, England : 1990). 40: 1170-8. PMID 15110880 DOI: 10.1016/J.Ejca.2003.12.026 |
0.34 |
|
| 2004 |
Rudek MA, Donehower RC, Statkevich P, Batra VK, Cutler DL, Baker SD. Temozolomide in patients with advanced cancer: phase I and pharmacokinetic study. Pharmacotherapy. 24: 16-25. PMID 14740784 DOI: 10.1592/Phco.24.1.16.34800 |
0.386 |
|
| 2004 |
Fracasso PM, Rudek MA, Naughton MJ, Picus J, Rader JS, Chen RC, Fears CL, Goodner SA, Dancey J, McLeod HL. Phase I study combining UCN-01 with irinotecan in resistant solid tumor malignancies Journal of Clinical Oncology. 22: 3139-3139. DOI: 10.1200/Jco.2004.22.90140.3139 |
0.391 |
|
| 2004 |
Rudek M, Smith N, Zhao M, He P, Lepper E, Figg W, Colevas A, Baker S, Sparreboom A. 520 Modulation of N,N-dimethylamino-benzoylphenylurea (BPU) absorption by the CYP3A and ABCG2 inhibitor ritonavir European Journal of Cancer Supplements. 2: 159. DOI: 10.1016/S1359-6349(04)80528-7 |
0.388 |
|
| 2004 |
Brahmer J, Baker S, Spitz A, Li J, Rudek M, Messersmith W, Wolff A, Laheru D, Donehower R, Hidalgo M. 366 Evaluation of Gefitinib biological effects in patients with solid tumors amenable to sequential biopsies Ejc Supplements. 2: 110. DOI: 10.1016/S1359-6349(04)80373-2 |
0.314 |
|
| 2003 |
Zhao M, Zabelina Y, Rudek MA, Wolff AC, Baker SD. A rapid and sensitive method for determination of dimethyl benzoylphenyl urea in human plasma by using LC/MS/MS. Journal of Pharmaceutical and Biomedical Analysis. 33: 725-33. PMID 14623599 DOI: 10.1016/S0731-7085(03)00424-2 |
0.35 |
|
| 2003 |
Rudek MA, Bauer KS, Lush RM, Stinson SF, Senderowicz AM, Headlee DJ, Arbuck SG, Cox MC, Murgo AJ, Sausville EA, Figg WD. Clinical pharmacology of flavopiridol following a 72-hour continuous infusion. The Annals of Pharmacotherapy. 37: 1369-74. PMID 14519054 DOI: 10.1345/Aph.1C404 |
0.528 |
|
| 2003 |
Rudek MA, Venitz J, Ando Y, Reed E, Pluda JM, Figg WD. Factors involved in the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer: clinical and experimental studies. Journal of Clinical Pharmacology. 43: 1124-35. PMID 14517195 DOI: 10.1177/0091270003256675 |
0.5 |
|
| 2003 |
Zhao M, He P, Rudek MA, Hidalgo M, Baker SD. Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B. 793: 413-420. PMID 12906916 DOI: 10.1016/S1570-0232(03)00356-8 |
0.316 |
|
| 2002 |
Purcell WT, Rudek MA, Hidalgo M. Development of matrix metalloproteinase inhibitors in cancer therapy Hematology-Oncology Clinics of North America. 16: 1189-1227. PMID 12512389 DOI: 10.1016/S0889-8588(02)00044-8 |
0.328 |
|
| 2002 |
Rudek MA, Venitz J, Figg WD. Matrix metalloproteinase inhibitors: do they have a place in anticancer therapy? Pharmacotherapy. 22: 705-20. PMID 12066962 DOI: 10.1592/Phco.22.9.705.34062 |
0.431 |
|
| 2002 |
Cianfrocca M, Cooley TP, Lee JY, Rudek MA, Scadden DT, Ratner L, Pluda JM, Figg WD, Krown SE, Dezube BJ. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 153-9. PMID 11773164 DOI: 10.1200/Jco.20.1.153 |
0.451 |
|
| 2001 |
Ghate JV, Turner ML, Rudek MA, Figg WD, Dahut W, Dyer V, Pluda JM, Reed E. Drug-induced lupus associated with COL-3: report of 3 cases. Archives of Dermatology. 137: 471-4. PMID 11295928 |
0.4 |
|
| 2001 |
Rudek MA, Horne M, Figg WD, Dahut W, Dyer V, Pluda JM, Reed E. Reversible sideroblastic anemia associated with the tetracycline analogue COL-3. American Journal of Hematology. 67: 51-3. PMID 11279658 DOI: 10.1002/Ajh.1076 |
0.486 |
|
| 2001 |
Rudek MA, Figg WD, Dyer V, Dahut W, Turner ML, Steinberg SM, Liewehr DJ, Kohler DR, Pluda JM, Reed E. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 19: 584-92. PMID 11208854 DOI: 10.1200/Jco.2001.19.2.584 |
0.525 |
|
| 2000 |
Bauer KS, Lush RM, Rudek MA, Shih C, Sausville E, Figg WD. A high-performance liquid chromatography method using ultraviolet and fluorescence detection for the quantitation of UCN-01, 7-hydroxystaurosporine, from human plasma and saliva. Biomedical Chromatography : Bmc. 14: 338-43. PMID 10960835 DOI: 10.1002/1099-0801(200008)14:5<338::Aid-Bmc993>3.0.Co;2-6 |
0.435 |
|
| 2000 |
Rudek MA, March CL, Bauer KS, Pluda JM, Figg WD. High-performance liquid chromatography with mass spectrometry detection for quantitating COL-3, a chemically modified tetracycline, in human plasma. Journal of Pharmaceutical and Biomedical Analysis. 22: 1003-14. PMID 10857569 DOI: 10.1016/S0731-7085(00)00257-0 |
0.442 |
|
| 2000 |
Kruger EA, Duray PH, Tsokos MG, Venzon DJ, Libutti SK, Dixon SC, Rudek MA, Pluda J, Allegra C, Figg WD. Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay. Biochemical and Biophysical Research Communications. 268: 183-91. PMID 10652234 DOI: 10.1006/Bbrc.1999.2018 |
0.42 |
|
| 1999 |
Lush RM, Rudek MA, Figg WD. Review of Three New Agents That Target Angiogenesis, Matrix Metalloproteinases, and Cyclin-Dependent Kinases. Cancer Control : Journal of the Moffitt Cancer Center. 6: 459-465. PMID 10758577 |
0.4 |
|
| 1999 |
RUDEK M, DYER V, HAMILTON J, PLUDA J, REED E, FIGG W. Preliminary pharmacokinetics (PK) of COL-3, a matrix metalloproteinase (MMP) inhibitor Clinical Pharmacology & Therapeutics. 65: 195-195. DOI: 10.1016/S0009-9236(99)80308-7 |
0.407 |
|
| Show low-probability matches. |